Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
08 juil. 2024 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
01 juil. 2024 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
03 juin 2024 14h30 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
02 juin 2024 12h30 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus Announces Pricing of Upsized Public Offering of Common Shares
29 mai 2024 21h30 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing...
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
29 mai 2024 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus N.V. Announces Proposed Public Offering of Common Shares
28 mai 2024 16h01 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing...
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
28 mai 2024 07h00 HE
|
Merus N.V.
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V....
Vorläufige Ergebnisse von Merus zu Petosemtamab in Kombination mit Pembrolizumab zeigen robuste Ansprechrate und günstiges Sicherheitsprofil bei Erstlinienbehandlung von rezidivierendem/metastasierendem HNSCC
28 mai 2024 07h00 HE
|
Merus N.V.
67 % Ansprechrate bei 24 auswertbaren Patienten beobachtet Telefonkonferenz am Dienstag, 28. Mai um 8 Uhr Eeastern Time UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 28, 2024 (GLOBE...
Les données intermédiaires du pétosemtamab de Merus en association avec le pembrolizumab démontrent un taux de réponse important et un profil d’innocuité favorable dans le traitement de première ligne du CETC r/m
28 mai 2024 07h00 HE
|
Merus N.V.
Taux de réponse de 67 % observé chez les 24 patients évaluables Conférence téléphonique le mardi 28 mai à 8 h, heure de l’Est UTRECHT, Pays-Bas, et CAMBRIDGE, Massachusetts, 28 mai 2024 (GLOBE...